On July 29th, Esperion held its inaugural investor day in New York City, with a tightly-packed agenda for the half-day event that included presentations from several of the world’s leading experts in their respective fields. It was an exciting and informative day!
Dr. James McKenney, President and CEO of National Clinical Research, and Professor Emeritus of the School of Pharmacy of Virginia Commonwealth University, kicked it off with a historical review of the management of LDL-cholesterol. Dr. McKenney also gave background on LDL-cholesterol as a biomarker, emphasizing that it is the number one modifiable lipid risk marker for cardiovascular disease. He also provided perspective on the ETC-1002 development program to date, which includes seven completed Phase 1 and Phase 2a clinical trials.
Dr. Mark McGovern, Former Executive Vice President, Medical Affairs, and Chief Medical Officer of KOS Pharmaceuticals, then gave an overview of our three on-going Phase 2 clinical trials of 1002, encompassing his perspective as both a cardiologist and a lipid-lowering drug developer. He also summarized our initial thoughts on the Phase 3 program for 1002.
As a practicing physician, Dr. Jamie Underberg, Clinical Assistant Professor of Medicine in the Division of General Internal Medicine at NYU Medical School, shared his unique perspective on statin intolerance, emphasizing the high incidence of the condition, and estimating 10% of patients who have taken a statin are actually intolerant. A video on statin intolerance featuring Dr. Paul Thompson from Hartford Hospital, an expert in statin intolerance, was shown at the end of Dr. Underberg’s talk. The video featured two statin-intolerant patients from Dr. Thompson’s practice and, as we like to say, helped put a face to statin intolerance. I encourage you to watch this informative video.
Dr. Greg Steinberg, Professor of the Division of Endocrinology, Department of Medicine, and Canada Research Chair in metabolism, obesity and type 2 diabetes at McMaster University, and Steve Pinkosky, Sr. Scientist and Head of Translational Research at Esperion, detailed the novel, first-in-class, dual mechanisms-of-action of 1002. For the first time for analysts and investors, they reviewed the more than 40-year history of ATP Citrate Lyase as a validated target for atherosclerosis research, and the more recent and intensive research into AMP Kinase as a validated target.
Dr. Peter Libby, Chief of Cardiovascular Medicine at Brigham and Women’s Hospital and the world’s leading expert on inflammation in cardiovascular disease, spoke about the importance of inflammation in atherosclerosis and why lowering hsCRP, a key risk marker of inflammation, is so important to the management of cardiovascular disease risk. Of note, only statins and 1002 have been shown to consistently lower both hsCRP and LDL-cholesterol.
In summary, the event provided investors with a deep dive into the mechanism of action for 1002 and the clinical rationale for its benefit in reducing LDL-cholesterol and hsCRP, as well as the opportunity to ask important questions of these experts. Overall, the information provided context for the upcoming Phase 2b top-line results, expected in early October, with results from our largest clinical trial to date—the Phase 2b ETC–1002–008 study in 349 statin intolerant and statin tolerant patients.
I have heard from many in attendance that they came away with both new insights and answers to many of their questions. I’m very pleased to hear that! If you were unable to attend or listen to the full webcast, I encourage you to visit the Investor section of our website at esperion.com to listen to a replay of the event, or simply listen to any particular presentation of interest outlined by topic and speaker below.
ETC-1002 Intro – Tim Mayleben[sc_embed_player_template1 fileurl=”http://www.esperion.com/wp-content/themes/esperion/mp3s/Esperion-Intro.mp3″]
ETC-1002 Clinical Program: Past & Present – Dr. James McKenney[sc_embed_player_template1 fileurl=”http://www.esperion.com/wp-content/themes/esperion/mp3s/Esperion-James-McKenny.mp3″]
ETC-1002 Clincal Program: Looking Forward – Dr. Mark McGovern[sc_embed_player_template1 fileurl=”http://www.esperion.com/wp-content/themes/esperion/mp3s/Esperion-Mark.mp3″]
The Reality of Statin Intolerance for Patients & Physicians – Dr. James Underberg[sc_embed_player_template1 fileurl=”http://www.esperion.com/wp-content/themes/esperion/mp3s/Esperion-James-Underberg.mp3″]
Clinical Q&A Panel[sc_embed_player_template1 fileurl=”http://www.esperion.com/wp-content/themes/esperion/mp3s/Esperion-Clinical-QandA.mp3″]
ETC-1002: Duel Mechanisms of Action Intro – Dr. Roger Newton[sc_embed_player_template1 fileurl=”http://www.esperion.com/wp-content/themes/esperion/mp3s/Esperion-ETC-1002-Intro.mp3″]
ETC-1002: Duel Mechanisms of Action – Stephen Pinkosky[sc_embed_player_template1 fileurl=”http://www.esperion.com/wp-content/themes/esperion/mp3s/Esperion-Stephen-Pinkosky.mp3″]
ETC-1002: Duel Mechanisms of Action – Dr. Greg Steinberg[sc_embed_player_template1 fileurl=”http://www.esperion.com/wp-content/themes/esperion/mp3s/Esperion-Greg-Steinberg.mp3″]
Inflammation & Cardiovascular Disease: New Perspectives – Dr. Peter Libby[sc_embed_player_template1 fileurl=”http://www.esperion.com/wp-content/themes/esperion/mp3s/Esperion-Peter-Libby.mp3″]
Pre-Clinical Q&A Panel[sc_embed_player_template1 fileurl=”http://www.esperion.com/wp-content/themes/esperion/mp3s/Esperion-Pre-Clinical-QandA.mp3″]